Nasdaq · CIK 0001813814
DFTX Definium Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 13 d ago. Close $36.90 on Oct 9, 2026, +246% from the 52-week low and -24% from the high.
Last 90 days
Net insider value
-$3.0M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
6
$3.0M by 5 insiders
Insiders on file
12
with a Form 4 at this company
Price and insider trades, last year
DFTXOct 9, 2026 · close 36.90
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Definium Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 45Moderate | Robert Barrow Chief Executive Officer sell | $1.2M 31,550 shares | -1% | - | |
| 27Weak | Brandi Roberts Chief Financial Officer sell | $123k 3,377 shares | -1% | - | |
| 28Weak | Mark Sullivan Chief Legal Officer sell | $514k 14,051 shares | -3% | - | |
| 20Weak | Matthew T. Wiley Chief Commercial Officer sell | $113k 3,097 shares | -1% | - | |
| 26Weak | Daniel Karlin Chief Medical Officer sell | $397k 10,853 shares | -1% | - | |
| 26Weak | Robert Barrow Chief Executive Officer sell | $722k 19,023 shares | -1% | - | |
| 22Weak | Robert Barrow Chief Executive Officer sell | $451k 24,431 shares | -3% | +278% from low-3% from high | |
| 35Weak | Robert Barrow Chief Executive Officer sell | $339k 25,791 shares | -3% | +167% from low-8% from high | |
| 18Weak | Daniel Karlin Chief Medical Officer sell | $74k 5,600 shares | -1% | +167% from low-8% from high | |
| 21Weak | Mark Sullivan Chief Legal Officer sell | $148k 11,276 shares | -4% | +167% from low-8% from high | |
| 33Weak | Robert Barrow Chief Executive Officer sell | $252k 25,797 shares | -3% | +100% from low-4% from high | |
| 18Weak | Daniel Karlin Chief Medical Officer sell | $75k 7,704 shares | -2% | +100% from low-4% from high | |
| 20Weak | Mark Sullivan Chief Legal Officer sell | $110k 11,278 shares | -4% | +100% from low-4% from high | |
| 32Weak | Robert Barrow Chief Executive Officer sell | $180k 26,491 shares | -3% | +40% from low-31% from high | |
| 17Weak | Daniel Karlin Chief Medical Officer sell | $53k 7,848 shares | -2% | +40% from low-31% from high | |
| 19Weak | Mark Sullivan Chief Legal Officer sell | $78k 11,491 shares | -4% | +40% from low-31% from high | |
| 24Weak | Robert Barrow Chief Executive Officer sell | $143k 21,208 shares | -2% | - | |
| 9Weak | Daniel Karlin Chief Medical Officer sell | $46k 6,836 shares | -2% | - | |
| 31Weak | Robert Barrow Chief Executive Officer sell | $142k 19,106 shares | -4% | - | |
| 17Weak | Daniel Karlin Chief Medical Officer sell | $49k 6,643 shares | -2% | - | |
| 10Weak | Carrie Liao Chief Accounting Officer sell | $17k 2,273 shares | -2% | - | |
| 16Weak | Mark Sullivan Chief Legal Officer sell | $34k 4,519 shares | -3% | - | |
| 18Weak | David W Gryska director buy | $18k 2,500 shares | +14% | - |
Transactions
The last 43 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 25, 2026 | Brandi Roberts Chief Financial Officer | SOpen-market sale Common Shares10b5-1 | -3,377 | $36.57 | $123k | 394,528 | 13 d ago |
| Sep 25, 2026 | Robert Barrow Chief Executive Officer | SOpen-market sale Common Shares10b5-1 | -31,550 | $36.57 | $1.2M | 2,213,090 | 13 d ago |
| Sep 25, 2026 | Daniel Karlin Chief Medical Officer | SOpen-market sale Common Shares10b5-1 | -10,853 | $36.57 | $397k | 792,846 | 13 d ago |
| Sep 25, 2026 | Mark Sullivan Chief Legal Officer | SOpen-market sale Common Shares10b5-1 | -14,051 | $36.57 | $514k | 494,228 | 13 d ago |
| Sep 25, 2026 | Matthew T. Wiley Chief Commercial Officer | SOpen-market sale Common Shares10b5-1 | -3,097 | $36.57 | $113k | 359,036 | 13 d ago |
| Sep 18, 2026 | Carol A Vallone director | MOption exercise Common Shares | +1,086 | $35.52 | $39k | 22,296 | 24 d ago |
| Sep 18, 2026 | Andreas Krebs director | MOption exercise Common Shares | +1,629 | $35.52 | $58k | 21,402 | 24 d ago |
| Sep 18, 2026 | Carol A Vallone director | MOption exercise Stock Option (Right to Buy)derivative | -1,086 | $0.00 | $0 | 0 | 24 d ago |
| Sep 18, 2026 | Andreas Krebs director | MOption exercise Stock Option (Right to Buy)derivative | -1,629 | $0.00 | $0 | 0 | 24 d ago |
| Sep 14, 2026 | Mark Sullivan Chief Legal Officer | AGrant or award Common Shares | +125,000 | $0.00 | $0 | 508,279 | 28 d ago |
| Sep 14, 2026 | Daniel Karlin Chief Medical Officer | AGrant or award Common Shares | +200,000 | $0.00 | $0 | 803,699 | 28 d ago |
| Sep 14, 2026 | Matthew T. Wiley Chief Commercial Officer | AGrant or award Common Shares | +125,000 | $0.00 | $0 | 362,133 | 28 d ago |
| Sep 14, 2026 | Brandi Roberts Chief Financial Officer | AGrant or award Common Shares | +125,000 | $0.00 | $0 | 397,905 | 28 d ago |
| Sep 14, 2026 | Robert Barrow Chief Executive Officer | AGrant or award Common Shares | +750,000 | $0.00 | $0 | 2,244,640 | 28 d ago |
| Sep 2, 2026 | Robert Barrow Chief Executive Officer | AGrant or award Common Shares10b5-1 | +40,000 | $0.00 | $0 | 1,513,663 | 38 d ago |
| Sep 3, 2026 | Robert Barrow Chief Executive Officer | SOpen-market sale Common Shares10b5-1 | -19,023 | $37.94 | $722k | 1,494,640 | 38 d ago |
| Mar 25, 2026 | Robert Barrow Chief Executive Officer | SOpen-market sale Common Shares10b5-1 | -24,431 | $18.47 | $451k | 752,454 | Mar 26, 2026 |
| Feb 3, 2026 | Robert Barrow Chief Executive Officer | AGrant or award Common Shares | +320,000 | $0.00 | $0 | 1,098,477 | Feb 5, 2026 |
| Jan 29, 2026 | Roger Adsett director | AGrant or award Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jan 29, 2026 |
| Dec 26, 2025 | Mark Sullivan Chief Legal Officer | SOpen-market sale Common Shares10b5-1 | -11,276 | $13.15 | $148k | 282,576 | Dec 29, 2025 |
| Dec 26, 2025 | Robert Barrow Chief Executive Officer | SOpen-market sale Common Shares10b5-1 | -25,791 | $13.15 | $339k | 778,477 | Dec 29, 2025 |
| Dec 26, 2025 | Daniel Karlin Chief Medical Officer | SOpen-market sale Common Shares10b5-1 | -5,600 | $13.15 | $74k | 425,025 | Dec 29, 2025 |
| Sep 25, 2025 | Robert Barrow Chief Executive Officer | SOpen-market sale Common Shares10b5-1 | -25,797 | $9.77 | $252k | 804,268 | Sep 26, 2025 |
| Sep 25, 2025 | Daniel Karlin Chief Medical Officer | SOpen-market sale Common Shares10b5-1 | -7,704 | $9.77 | $75k | 430,625 | Sep 26, 2025 |
| Sep 25, 2025 | Mark Sullivan Chief Legal Officer | SOpen-market sale Common Shares10b5-1 | -11,278 | $9.77 | $110k | 293,852 | Sep 26, 2025 |
| Jun 25, 2025 | Robert Barrow Chief Executive Officer | SOpen-market sale Common Shares10b5-1 | -26,491 | $6.80 | $180k | 830,065 | Jun 26, 2025 |
| Jun 25, 2025 | Daniel Karlin Chief Medical Officer | SOpen-market sale Common Shares10b5-1 | -7,848 | $6.80 | $53k | 438,329 | Jun 26, 2025 |
| Jun 25, 2025 | Mark Sullivan Chief Legal Officer | SOpen-market sale Common Shares10b5-1 | -11,491 | $6.80 | $78k | 305,130 | Jun 26, 2025 |
| Jun 12, 2025 | Andreas Krebs director | AGrant or award Stock Option (Right to Buy)derivative | +75,187 | $0.00 | $0 | 75,187 | Jun 16, 2025 |
| Jun 12, 2025 | Carol A Vallone director | AGrant or award Stock Option (Right to Buy)derivative | +75,187 | $0.00 | $0 | 75,187 | Jun 16, 2025 |
| Jun 12, 2025 | David W Gryska director | AGrant or award Stock Option (Right to Buy)derivative | +75,187 | $0.00 | $0 | 75,187 | Jun 16, 2025 |
| Jun 12, 2025 | Roger Crystal director | AGrant or award Stock Option (Right to Buy)derivative | +75,187 | $0.00 | $0 | 75,187 | Jun 16, 2025 |
| Jun 12, 2025 | Suzanne Louise Bruhn director | AGrant or award Stock Option (Right to Buy)derivative | +75,187 | $0.00 | $0 | 75,187 | Jun 16, 2025 |
| Jun 2, 2025 | Brandi Roberts Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +500,000 | $0.00 | $0 | 500,000 | Jun 2, 2025 |
| Mar 25, 2025 | Robert Barrow Chief Executive Officer | SOpen-market sale Common Shares10b5-1 | -21,208 | $6.74 | $143k | 856,556 | Mar 26, 2025 |
| Mar 25, 2025 | Daniel Karlin Chief Medical Officer | SOpen-market sale Common Shares10b5-1 | -6,836 | $6.74 | $46k | 446,177 | Mar 26, 2025 |
| Mar 12, 2025 | Robert Barrow Chief Executive Officer | AGrant or award Common Shares | +350,000 | $0.00 | $0 | 877,764 | Mar 13, 2025 |
| Mar 12, 2025 | Daniel Karlin Chief Medical Officer | AGrant or award Common Shares | +115,000 | $0.00 | $0 | 453,013 | Mar 13, 2025 |
| Dec 26, 2024 | Robert Barrow Chief Executive Officer | SOpen-market sale Common Shares10b5-1 | -19,106 | $7.43 | $142k | 526,666 | Dec 27, 2024 |
| Dec 26, 2024 | Daniel Karlin Chief Medical Officer | SOpen-market sale Common Shares10b5-1 | -6,643 | $7.43 | $49k | 338,013 | Dec 27, 2024 |
| Dec 26, 2024 | Carrie Liao Chief Accounting Officer | SOpen-market sale Common Shares10b5-1 | -2,273 | $7.43 | $17k | 97,270 | Dec 27, 2024 |
| Dec 26, 2024 | Mark Sullivan Chief Legal Officer | SOpen-market sale Common Shares10b5-1 | -4,519 | $7.43 | $34k | 173,197 | Dec 27, 2024 |
| Dec 5, 2024 | David W Gryska director | POpen-market purchase Common Shares | +2,500 | $7.17 | $18k | 19,851 | Dec 5, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Roger Adsettcoo, officer, director
- Robert BarrowChief Executive Officer
- Suzanne Louise Bruhndirector
- Roger Crystaldirector
- David W Gryskadirector
- Daniel KarlinChief Medical Officer
- Andreas Krebsdirector
- Carrie LiaoChief Accounting Officer
- Brandi RobertsChief Financial Officer
- Mark SullivanChief Legal Officer
- Carol A Vallonedirector
- Matthew T. WileyChief Commercial Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.